Loading...

RAPP RAPPORT THERAPEUTICS INC Expansion Plans 8-K Filing

RPPR

RPP

RAPPORT THERAPEUTICS INC

(RAPP)

2025 8-K

Financial Results Update

Seizure Reduction Results

Financial Results Update

Stock Offering Announcement

Program Expansion

Financial Results Announced

Stock Offering Update

Sales Agreement Termination

Positive Clinical Results

Financial Statements

Product Expansion

Financial Statements

Financial Results

Management Update

Financial Results

External Links:

On September 8, 2025, Rapport Therapeutics, Inc. reported positive results from their Phase 2a trial of RAP-219 for focal onset seizures, showing that 85.2% of patients had a significant reduction in seizure episodes. The filing also noted the company plans to advance to Phase 3 trials in 2026.

AI Assistant

RAPPORT THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.